Last €49.93 EUR
Change Today +0.099 / 0.20%
Volume 50.0
JUD On Other Exchanges
New York
As of 4:25 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

Saint Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular (CV) medical devices for the global cardiac rhythm management (CRM), CV and atrial fibrillation (AF) therapy areas and neurostimulation medical devices for the management of chronic pain. The company’s primary products in each therapy area include CRM – tachycardia implantable cardioverter defibrillator systems (ICDs) and bradycardia pacemaker systems (pacemakers); CV – vascular products, which include vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs, and other vascular accessories, and structural heart products, which include heart valve replacement and repair products and structural heart defect devices; AF – electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems; and Neuromodulation (NMD) – neurostimulation products, which include spinal cord and deep brain stimulation devices. Principal Products CRM CRM focuses on the research, development, and manufacture of products for cardiac arrhythmias, or irregular heartbeats. The company’s CRM product line includes ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect its devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; implantable loop recorders that monitor a patient's heart rhythm through a set period of time in order to provide major information into underlying pathologies, such as bradycardia, AF, and other cardiac arrhythmias; and programmers and remote monitoring equipment, which are used by physicians and healthcare professionals to program its CRM devices and analyze device data to improve patient management. The company’s ICDs and CRT defibrillator (CRT-D) devices treat patients with hearts that beat inappropriately fast, a condition known as tachycardia. ICDs monitor the heartbeat and deliver high energy electrical impulses, or ‘shocks’, to treat potentially lethal, abnormally fast heart rhythms (ventricular tachycardia (VT) and ventricular fibrillation (VF)), which lead to sudden cardiac death (SCD). ICDs and CRT-Ds are implanted underneath the collarbone and connected to the heart by leads that deliver electrical impulses to the heart, regulating its rhythm. During 2012, the company received U.S. Food and Drug Administration (FDA) and European CE Mark approval for the Ellipse ICD, as well as the Assura family of ICD and CRT-D devices. The Assura family of high-voltage devices features both ICD models (Fortify Assura) and CRT-D models (Unify Assura for bi-polar CRT-D and Quadra Assura for quadripolar CRT-D). The Ellipse ICD is a high energy ICD denoted for its small size while the Assura family has a high energy output, with a maximum output of 40 Joules. Both Ellipse and Assura devices feature advanced algorithms for discerning, which arrhythmias need defibrillation therapy. These new ICDs also offer the new SecureSense algorithm that could both detect and notify the patient and/or physician of lead problems. The Assura families also include the company’s Unify Quadra CRT-D device (FDA and European CE Mark approvals) and its Quartet LV (left ventricular) lead (FDA and European CE Mark approvals). Its Unify Quadra, Quadra Assura, and Promote Quadra represent its quadripolar pacing systems and are available worldwide. These quadripolar pacing systems allow physicians various options to address pacing complications without the need to reposition a lead surgically. The Assura family replaces the company’s Unify CRT-D and Fortify ICD devices (FDA and European CE Mark approvals). In addition, the Fortify ST (European CE Mark approval) and Ellipse ST ICDs (models commercialized outside the U.S. only) are capable of monitorin


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €49.93 EUR +0.099

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $12.85 USD +0.30
Coloplast A/S kr485.70 DKK +2.50
Smith & Nephew PLC 1,051 GBp +3.00
Terumo Corp ¥2,313 JPY +19.00
Zimmer Holdings Inc $102.17 USD +0.75
View Industry Companies

Industry Analysis


Industry Average

Valuation JUD Industry Range
Price/Earnings 21.6x
Price/Sales 3.5x
Price/Book 4.8x
Price/Cash Flow 21.1x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at